Quick Facts

• Provides temporary relief of discomfort in the area of application.
• Used to manage pain and itching associated with minor burns, cuts, scrapes, and insect bites.
• May be utilized to support pain control for certain procedures on mucosal surfaces.

---

Xylocain 5% (lidocaine) ointment is indicated for providing local, topical anesthesia to address pain and discomfort. It is typically applied to specific skin or mucosal areas to support the reduction of temporary pain and itching. This formulation is used in the management of irritation caused by minor superficial issues, such as small cuts, abrasions, mild sunburn, and the discomfort associated with insect bites.

Additionally, Xylocain ointment may be incorporated into pain prevention strategies for minor medical procedures. Its primary function is to modulate sensation at the site of application.

Eligibility Map: Who can and cannot use Xylocain 5% — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

• Adults and children, provided that for pediatric and compromised patients, the dose is reduced commensurate with their physical status.

Populations for whom use is not recommended (if applicable):

• Use in children under two years of age is not recommended, as there is insufficient data to support safety and efficacy in this patient population.

Populations for whom use is contraindicated:

• Patients with a known history of hypersensitivity to local anesthetics of the amide type (e.g., lidocaine) or to any component of the ointment.
• Patients with congenital or idiopathic methemoglobinemia or Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Age-related eligibility rules:

• Children Under 2 Years: Use requires caution due to insufficient safety/efficacy data.
• Elderly (Geriatric): Requires reduced doses commensurate with physical condition.

Condition-specific eligibility rules:

• Severe Hepatic Disease: Use requires caution due to risk of increased systemic concentrations from impaired metabolism.
• Severe Shock or Heart Block: Requires caution due to the potential for systemic effects on cardiovascular function.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy (Category B): Lidocaine crosses the placental barrier. Caution is advised during early pregnancy.
• Lactation (Breastfeeding): It is not known whether the drug is excreted in human milk from this specific formulation; caution is advised for nursing women.

Eligibility-related restrictions:

• Debilitated or Acutely Ill Patients: Must receive reduced doses.
• Application to Non-Intact Skin: Use with caution on broken or inflamed skin due to increased risk of systemic absorption.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated (Absolute prohibition based on allergy/metabolic disorder)
• Conditional Use / Caution (Restriction based on age/hepatic/cardiac status)
• Reduced Dose Requirement (Restriction based on age/physical status)

Official eligibility statements:

• The medicine is contraindicated in patients with a history of hypersensitivity to amide-type local anesthetics.
• Use requires caution and reduced doses in elderly, acutely ill, and debilitated patients commensurate with their physical condition.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use Xylocain 5% by establishing absolute contraindications based on known allergic and metabolic risk factors. For populations with compromised liver or cardiac function, or those at the extremes of age or physical condition, the medicine’s eligibility is strictly limited by mandated conditional use and the requirement for a reduction in dose. These regulations restrict the population to those where the risk of systemic toxicity can be managed.

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Xylocain 5% primarily through pharmacokinetic alterations and additive pharmacodynamic effects. There are no medicinal products explicitly listed as an absolute drug-drug contraindication for the topical ointment.

Metabolic and Exposure-Modifying Interactions

Lidocaine is cleared through metabolic pathways involving the CYP450 3A4 and 1A2 enzymes. Co-administration with medicinal products that inhibit these enzymes, such as certain Protease Inhibitors or Erythromycin, may significantly reduce clearance, resulting in increased systemic exposure and higher plasma concentrations. Conversely, enzyme inducers may accelerate clearance. A documented substance interaction notes that Grapefruit or Grapefruit Juice may increase plasma concentrations by inhibiting the CYP450 3A4 pathway.

Additive Pharmacodynamic Effects and Restrictions

The label formally states that the toxic effects of Xylocain 5% are additive when used concurrently with other local anesthetic agents. Additionally, co-administration with Methemoglobinemia-inducing agents, which include Nitrates/Nitrites, Dapsone, and specific Antibiotics, increases the risk of methemoglobinemia due to additive oxidizing effects.

Constraints and Population Notes

An official administration constraint requires that if the ointment is applied to the oral or pharyngeal mucosa, food or chewing gum must be avoided for 60 minutes to mitigate the physical risk of aspiration or biting trauma. Patients with severe hepatic impairment are noted as being at a greater risk of developing toxic blood concentrations due to the drug's impaired metabolic elimination.

Molecular Blockade of Sodium Channels

The mechanism of action centers on the voltage-gated sodium channels ( Nav), which are essential for transmitting electrical signals in nerve cells. Lidocaine, the active ingredient, binds within the intracellular pore of these channels, resulting in non-competitive inhibition. This binding physically obstructs the flow of sodium ions, which is the necessary step for the nerve cell membrane to electrically discharge (depolarize) and fire an impulse. This targeted action initiates the mechanistic cascade that prevents the electrical signaling.

Interruption of Nociceptive Signal Conduction

By preventing the influx of sodium ions, the drug directly stabilizes the nerve cell membrane, making it non-responsive to external stimuli. This immediate action effectively halts the initiation and propagation of the action potential along the peripheral sensory nerve fibers (nociceptive signaling pathway). The resultant physiological consequence is a transient and reversible conduction block, which ensures that peripheral afferent signals (sensory inputs) fail to propagate to the central nervous system.

Mechanism Dependence on Local Tissue Conditions

The ability of Lidocaine to reach its intracellular target is critically dependent on its chemical equilibrium, which is affected by the local tissue pH. In acidic environments, such as those caused by inflammation or infection, the ratio of the necessary penetrating form is reduced, which results in a reduced functional block of Nav channels.

Xylocain 5% is an ointment formulation intended strictly for topical administration to the skin or accessible mucous membranes. This route of application encompasses use on oromucosal surfaces and external application for specific conditions, such as anorectal disorders.

Official Dosing Limits and Frequency

The administration protocol is rigidly defined by dose limitations to ensure proper use. The maximum single application of the 5% ointment is limited to 5 grams (equivalent to 250 mg of lidocaine base), often visually described as approximately a six-inch length of ointment squeezed from the tube. The total cumulative amount applied in a 24-hour period must not exceed 20 grams (1000 mg lidocaine). Application is typically performed three to four times daily on an as-needed basis for symptom control, though some external uses may allow up to six applications daily, provided the cumulative 24-hour maximum is strictly respected.

Administration Techniques and Adjustments

The preparation must be applied as a thin layer to the treatment area. For applications involving broken skin, official instructions recommend using a sterile gauze pad for proper application. It is a requirement to consider the total drug exposure from all concurrently used lidocaine-containing products toward the daily maximum limit. Dosage adjustments are officially required for specific populations: older adults and debilitated patients should receive reduced amounts commensurate with their physical condition. For pediatric patients (aged 2 to 12 years), the single dose must be calculated and should not exceed 4.5 mg of lidocaine per kg of body weight. The overarching principle is to utilize the lowest dosage that provides effective anesthesia.

Research Evidence / Overview of Studies for Xylocain 5%

Evidence for Temporary Relief of Pain and Itching from Minor Skin Issues

The research base includes a number of short-term studies, often conducted during the initial regulatory evaluation of the active ingredient, lidocaine. These studies was monitored in research exploring how symptoms change over time in populations in the context of minor abrasions, insect bites, or mild sunburn. The research examined patient-reported outcomes describing perceived discomfort and how symptoms evolved in the observed populations immediately after application.

Studies reported measurements of patterns related to numbing and localized sensory change following application compared to a non-medicated vehicle (placebo) in these short-term settings. It is important to note that many of the original studies that established this use are historical, meaning evidence quality varies across studies, and some studies do not align with current, large-scale clinical trial methods.

Evidence for Anesthesia of Accessible Mucous Membranes

The use of this ointment to achieve numbing before medical procedures was studied for in specialized clinical trials and regulatory assessments. These studies were conducted specifically to evaluate the effect of the ointment when applied to accessible mucosal surfaces. The studies monitored patient-reported outcomes describing episodic or acute changes in sensation, such as the onset time of numbing and the duration of the sensory blockade achieved. Research describes patterns related to short-term changes that may be observed during medical examinations or minor operative procedures.

What Remains Uncertain in the Research Record

The existing evidence base contains several acknowledged research gaps. Long-term effects are not fully established because the primary research focus was on immediate, temporary symptom changes. Furthermore, comparative evidence is lacking in modern, head-to-head clinical trials that directly compare the 5% ointment formulation against many current topical alternatives. Studies of the 5% ointment are often limited to short-term, acute observations in specific anatomical sites, and data for certain groups remain insufficient, especially children under two years old.

Key Studies & References

1. Lidocaine Ointment USP, 5% FOR TOPICAL USE DO NOT USE IN THE EYES Rx Only - DailyMed (FDA Label)
2. LIDOCAINE OINTMENT USP, 5% - DailyMed (FDA Label/Indications)

Common questions about Xylocain 5% (FAQ)

Q: How quickly does Xylocain 5% usually start working?

A: Official product information, based on studies of the active ingredient, indicates that the onset of topical numbing, or local anesthesia, typically occurs within 3 to 5 minutes after the ointment is applied to the treatment area.

Q: How long does the numbing effect of Xylocain 5% last?

A: Regulatory documents describe the intended effect as providing temporary relief for the condition being treated. The exact duration of the numbing effect can be influenced by the specific area of the body where the ointment is applied and the total amount used.

Q: What happens if Xylocain 5% is left on for too long?

A: Excessive dosage or short intervals between doses is associated with high systemic exposure to the active ingredient. This systemic exposure may lead to serious adverse effects, and may manifest as signs of central nervous system or cardiovascular toxicity.

Q: Can Xylocain 5% affect the heart or blood pressure?

A: High levels of the active ingredient in the bloodstream may affect the cardiovascular system. Official documents indicate that excessive blood concentrations may cause changes in blood pressure (hypotension) and heart rate (bradycardia). This risk is associated with improper or extended use.

Q: Can Xylocain 5% be used while breastfeeding?

A: Lidocaine is generally considered acceptable for use during breastfeeding in published data. Official guidance includes the necessity of thoroughly washing the product off the breast or nipple area prior to feeding an infant to minimize potential exposure.

Q: Are there studies on the long-term use of Xylocain 5%?

A: Official regulatory submissions and research records primarily focus on short-term, temporary changes in symptoms. Studies to evaluate the long-term potential for topical lidocaine to cause cancer in animals were not conducted, meaning the effects of long-term use for this topical formulation are not fully established in the research record.

Q: What is the distinction between Xylocain 5% and lidocaine patches used for purposes other than postherpetic neuralgia?

A: The Xylocain 5% ointment formulation is an anesthetic indicated for localized numbing of accessible mucous membranes and minor skin issues. Lidocaine patches (a different formulation) have a separate, specific regulatory indication for conditions such as pain after shingles (post-herpetic neuralgia).

Q: What conditions is Xylocain 5% officially approved to treat?

A: According to the official product label, the 5% ointment is indicated for the temporary production of anesthesia on accessible mucous membranes (such as the mouth or throat). It is also approved for the temporary relief of pain associated with minor, localized skin issues like burns, abrasions, and insect bites.

Q: Why do official documents state Xylocain 5% should only be used once a day?

A: Official frequency guidelines for the 5% ointment typically indicate application up to three to four times daily as needed, which clarifies a common misconception about the use frequency. However, the total amount used over a 24-hour period has a defined maximum limit, regardless of how often it is applied.

Q: Can Xylocain 5% be bought over the counter?

A: No, the Xylocain 5% ointment formulation is classified as a Prescription only (Rx) medicine in the United States and similar regulatory territories. This means it requires a prescription from a licensed healthcare professional.

Q: Why is Xylocain 5% used for pain after shingles?

A: The Xylocain 5% ointment formulation is not indicated for the treatment of pain after shingles (post-herpetic neuralgia). That specific indication is approved for a separate lidocaine product, such as the 5% medicated patch.

Q: Can Xylocain 5% be used on open cuts or broken skin?

A: Official warnings describe that the ointment should be used with extreme caution if the skin or mucous membrane is severely injured, inflamed, or compromised. Application to non-intact skin carries an increased potential for rapid systemic absorption, which may lead to toxic blood levels.

Q: Is a prescription always required for Xylocain 5%?

A: Yes, regulatory classification defines the Xylocain 5% ointment as a prescription-only (Rx) product. It is not available for retail purchase without proper authorization from a healthcare professional.

Q: What kind of sensations are considered 'normal' when using Xylocain 5%?

A: The primary purpose of the medicine is to achieve localized numbness at the application site. Official documents classify common application site reactions as localized issues like temporary irritation, redness, or rash. These are the most frequently observed effects.

Q: Does Xylocain 5% cause a burning sensation upon application?

A: Official safety data documents that localized application site reactions, including a burning sensation or irritation, are classified as common adverse events for topical lidocaine formulations.

Q: Can physical activities affect how Xylocain 5% works?

A: Studies examining similar topical lidocaine delivery systems have assessed this factor. In one study, physical activity was found to have no effect on the systemic exposure (amount in the bloodstream) of the drug, suggesting a consistent effect regardless of movement.

Q: Is it normal to see redness or irritation where the patch was applied?

A: Localized skin reactions at the application site, such as redness (erythema) and minor irritation, are officially documented as common adverse events. Therefore, experiencing these temporary effects is not unusual.

Q: Does alcohol consumption affect the use of Xylocain 5%?

A: Official prescribing information and regulatory guidance do not list a specific, explicit interaction between alcohol consumption and the safe topical use of Xylocain 5% ointment.

Q: Are there any specific skin types that should avoid using Xylocain 5%?

A: Official warnings focus on the condition of the skin, rather than on specific skin types. Caution is advised if the ointment is applied to skin that is broken, severely inflamed, or otherwise compromised, due to an increased risk of absorption.

Q: Is Xylocain 5% known to interact with herbal supplements?

A: Due to a lack of specific regulatory testing, there is insufficient information to confirm interactions between complementary medicines, herbal remedies, or supplements and the lidocaine ointment.

Q: How is Xylocain 5% absorbed by the body?

A: The active ingredient, lidocaine, is absorbed through the skin following topical application. The rate and extent of absorption are influenced by the specific site of application, the concentration of the ointment, the total amount applied, and the duration of exposure.

Q: Is Xylocain 5% recommended for acute pain or only chronic pain?

A: The 5% ointment is officially indicated for the temporary relief of pain associated with minor, short-term issues such as insect bites or minor abrasions. This use aligns with addressing acute, localized symptoms.

Q: Can Xylocain 5% be used with heat packs or heating pads?

A: Studies on similar topical lidocaine products have observed that exposure to external heat, such as a heating pad, may result in increased systemic plasma concentrations of the active ingredient.

Q: Is Xylocain 5% a controlled substance?

A: No, the active ingredient in Xylocain 5%, lidocaine, is not classified as a controlled substance under the federal Controlled Substances Act or similar regulatory bodies internationally.

Q: Can Xylocain 5% cause temporary changes in skin color?

A: Adverse reactions documented in the safety profile include the possibility of methemoglobinemia (a blood disorder), which is associated with temporary discoloration, such as a bluish color to the lips, fingernails, or palms.

Q: What does it mean that Xylocain 5% is a 'patch'?

A: Xylocain 5% is a topical ointment (a semisolid cream), not a patch. This medicine is designed for direct application to the skin or mucous membranes. Patches are a different type of dosage form containing lidocaine and have separate approved uses.

Q: Why do people with certain medical conditions advised against using Xylocain 5%?

A: Official warnings describe that caution is needed for populations with conditions such as severe hepatic impairment (liver dysfunction) or severe cardiac impairment. This is due to the drug being metabolized by the liver; impairment may slow its clearance, thereby creating a potential for toxic blood concentrations.

Q: What is the official definition of the term 'postherpetic neuralgia' that Xylocain 5% treats?

A: Postherpetic neuralgia (PHN) is a term used to describe chronic pain that persists after the rash and blisters from a bout of shingles have healed. It is important to note that the Xylocain 5% ointment is not indicated for the treatment of this specific condition.

Official Storage and Disposal Requirements

This information reflects the mandatory requirements for Xylocain 5% Ointment as defined in regulatory labeling.

Storage Category	Official Requirement
Temperature & Environment	Store in a cool place, typically at or below 25 C (77 F). Protect from freezing, excessive heat, and moisture.
Packaging & Stability	Keep the container tightly closed and in its original packaging. Do not use the ointment past the expiry date printed on the label.
Protection	The product must be stored out of the sight and reach of children.
Disposal	Do not dispose of unused or expired medicine in household trash or pour it down a sink or toilet. Return the product to a pharmacist or local collection program for proper, environmentally safe disposal, in accordance with local regulations.

---

Storage Summary: The product's stability is maintained by strict temperature control and protection from environmental exposure. Used or expired product must be handled through official collection channels to prevent environmental contamination, as required by regulatory agencies.